Q&A With David Melnick From Allergan: Update On Potential Antibiotic Resistance Drug And the Future Of The Field

One of the biggest challenges hospitals today face is winning the battle of antimicrobial stewardship and infections like MRSA. Work continues to develop medications to help treat these patients and keep others in the hospital system safe.

One of the biggest challenges hospitals today face is winning the battle of antimicrobial stewardship and infections like MRSA. Work continues to develop medications to help treat these patients and keep others in the hospital system safe.

David Melnick, MD, who serves as Vice President of Clinical Development and Anti-Infectives at Allergan discussed work his company is doing in this field and what work remains to be done during the annual Infectious Disease Week conference in San Diego.

When treating patients various antibiotic issues there is a need for a variety of medications available to treat them. Companies like Allergan who have multiple treatments in their portfolio can provide the care needed for these conditions to help patients in a cost effective manner.

In addition to finding new treatment options for medical concerns like antibiotic resistance and antimicrobial stewardship there can also be changes to dosage and the way already existing medications are delivered. At ID Week it was announced that Allergan had applied for a change in Dalvance's delivery which could provide more flexibility for doctors to give their patients.